Johnson & Johnson (JNJ) News
Track canonical SquawkNews coverage tagged to JNJ, Johnson & Johnson. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 128 indexed stories across 45 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Novo and Orbis sign up to $1.4B deal for oral therapies
Orbis Medicines signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases traditionally treated with injectable drugs.
MNA | Sep 17, 2026, 11:00 AM UTC
M
Legend Biotech names Ingrid Zhang CEO
Legend Biotech (LEGN) appointed Ingrid Zhang as chief executive on Tuesday, ending a two-month search after former CEO Ying Huang resigned in July.
EQUITY | Sep 15, 2026, 11:40 PM UTC
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
H
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ: CTNM ) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical up
LIVE | Sep 15, 2026, 03:07 PM UTC
M
Autumn in New York: Factory expansion slows, input prices at multi-year highs - Empire State
AUTUMN IN NEW YORK: FACTORY EXPANSION SLOWS, INPUT PRICES AT MULTI-YEAR HIGHS - EMPIRE STATEInvestors began their Tuesday with a relatively minor chunk of economic data courtesy of a report from the New York Federal Rese
NEWS | Sep 15, 2026, 02:53 PM UTC
L
US stock indexes swing lower as oil, yields jump
U.S. STOCK INDEXES SWING LOWER AS OIL, YIELDS JUMPWall Street's three main indexes turned lower on Tuesday, with the Dow Industrials DJ:DJI leading losses amid broad pressure from a rally in oil prices and climbing Treas
COMMODITIES | Sep 15, 2026, 02:27 PM UTC
L
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech NASDAQ:LEGN on Tuesday appointed longtime Novartis BX:NOT executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy C
NEWS | Sep 15, 2026, 12:43 PM UTC
L
HBA India Summit Calls For Leaders To Command The AI Shift
Hyderabad summit highlights AI, GCCs, commercial acumen and influence as India takes on a larger role in global healthcare leadershipThe Healthcare Businesswomen’s Association (HBA) India hosted the third edition of its
NEWS | Sep 15, 2026, 08:32 AM UTC
L
JNJ Reports Low Rates Of Treatment-Related Events For Rybrevant Faspro Plus Lazcluze At Wclc 2026
Johnson & Johnson NYSE:JNJ
NEWS | Sep 15, 2026, 03:03 AM UTC
L
JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
NEWS | Sep 15, 2026, 03:00 AM UTC
L
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics NASDAQ:CTNM said on Monday an experimental depression drug it developed with Johnson & Johnson NYSE:JNJ failed to meet the main goal of a mid-stage study.
NEWS | Sep 14, 2026, 08:11 PM UTC
L
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significan
NEWS | Sep 14, 2026, 08:05 PM UTC
L
J&J Says Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival In EGFR Exon 20 Insertion NSCLC
Johnson & Johnson NYSE:JNJ
NEWS | Sep 14, 2026, 01:47 AM UTC
L
JNJ - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation- positive lung cancer
JNJ - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation- positive lung cancer
NEWS | Sep 14, 2026, 01:45 AM UTC
L
J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion — WSJ
By Lauren Thomas and Alex JaninPrivate-equity firm Apollo Global Management is in talks to acquire Johnson & Johnson's hips-and-knees parts business for around $20 billion, according to people familiar with the matter.J&
MNA | Sep 12, 2026, 07:41 PM UTC
L
Apollo in talks to acquire J&J’s orthopedics unit
Apollo Global Management NYSE:APO is in talks to acquire Johnson & Johnson's NYSE:JNJ DePuy Synthes orthopedics unit in a deal that could value it at close to $20B, Bloomberg reported late Friday.An agreement could be
MNA | Sep 12, 2026, 12:14 AM UTC
L
JNJ Stock Edges Up After-Hours On Apollo’s $20B Orthopedics Talks
Johnson & Johnson shares edged higher after the close on Friday as investors digested a late report that Apollo Global Management is in talks to buy the company’s orthopedics business.The stock finished regular trading a
EQUITY | Sep 11, 2026, 11:47 PM UTC
L
Apollo Global in talks to acquire J&J's orthopedics unit, Bloomberg News reports
Apollo Global Management NYSE:APO is in discussions to acquire Johnson & Johnson's NYSE:JNJ orthopedics unit in a deal that could value the unit at close to $20 billion, Bloomberg News reported on Friday, citing sources.
MNA | Sep 11, 2026, 10:41 PM UTC
L
Apollo Global Is Said In Talks To Acquire J&J’s Orthopedics Unit - Bloomberg News
Apollo Global Is Said In Talks To Acquire J&J’s Orthopedics Unit - Bloomberg News
MNA | Sep 11, 2026, 10:37 PM UTC
L
Jaguar LAA Investors Include Santé Ventures
Jaguar LAA Investors Include Santé Ventures
NEWS | Sep 11, 2026, 08:04 PM UTC
L
Jaguar LAA Buys Assets Related to Laminar Program From Johnson & Johnson
Jaguar LAA Buys Assets Related to Laminar Program From Johnson & Johnson
NEWS | Sep 11, 2026, 08:03 PM UTC
H
AM Markets Need to Know: Diesel tops $6, DeepSeek pressures chips, and more
Stock index futures were higher on Friday as investors awaited the consumer inflation report, while Oracle posted stronger-than-expected quarterly results and guidance.Here are the five news items investors should watch:
MACRO | Sep 11, 2026, 10:01 AM UTC
L
JNJ receives CE Marking for ACUVUE OASYS MAX 2-Week
Johnson & Johnson said it received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens using proprietary MAX technologies. The company said the lens is designed for comfort and visual clarity even at day
EQUITY | Sep 10, 2026, 02:31 PM UTC
L
HSBC raises Johnson & Johnson price target to $320 from $290
HSBC raised its Johnson & Johnson price target to $320.00 per share from $290.00, according to TradingView News as cited by Benzinga. The rating was maintained at Buy.
EQUITY | Sep 10, 2026, 01:53 PM UTC
L
Johnson & Johnson wins CE mark as new ACUVUE contact lens nears Europe launch
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 10, 2026, 01:02 PM UTC
L
Johnson & Johnson receives CE marking for ACUVUE OASYS MAX 2-week
Johnson & Johnson said it received CE marking for ACUVUE OASYS MAX 2-week, a reusable contact lens with MAX technologies designed for comfort and visual clarity up to day 14. The lens will be rolled out in select Europe.
EQUITY | Sep 10, 2026, 11:45 AM UTC
L
JNJ: Focused on high-growth MedTech markets, innovation, and portfolio shifts, strong growth is projected
MedTech is on track for high-end growth, driven by a focused shift into cardiovascular, surgery, and vision, with robust innovation and a new operating model. Despite competitive and geopolitical headwinds, confidence re
EQUITY | Sep 09, 2026, 04:25 PM UTC
L
JNJ MedTech targets high-end growth via cardiovascular, surgery and vision
MedTech is on track for high-end growth backed by innovation and a new business-unit structure, with a focus on cardiovascular, surgery and vision despite competitive and geopolitical headwinds.
EQUITY | Sep 09, 2026, 03:57 PM UTC
H
JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 - Clic
JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
GEOPOLITICS | Sep 08, 2026, 12:01 PM UTC
H
DELAYED UPDATE — UBS raises JNJ price target to $320 ahead of Q3 results
Johnson & Johnson will release Q3 results Oct. 13, with a 6:45 a.m. ET press release and 8:30 a.m. ET earnings call/webcast. UBS raised its price target to $320 from $280.
EARNINGS | Sep 07, 2026, 11:23 AM UTC
L
JNJ EVP sold MedTech shares worth $9,230,439 at $274.74
JNJ officer Timothy Schmid executed two direct sales of common stock on September 2, 2026 at $274.74 per share, totaling $9,230,439. After the trades, Schmid owned 25,447 shares directly.
EQUITY | Sep 04, 2026, 01:32 PM UTC
L
J&J rises about 1% after AbbVie myeloma drug 74% response
Johnson & Johnson rose roughly 1% to $277.955 Thursday afternoon after AbbVie’s experimental multiple-myeloma drug etentamig showed a 74% response rate, lowering the risk of disease progression or death.
CENTRAL_BANK | Sep 03, 2026, 09:26 PM UTC
L
Johnson & Johnson to participate in Deutsche Bank 2026 Healthcare Summit
Johnson & Johnson plans to participate in the Deutsche Bank 2026 Healthcare Summit.
EQUITY | Sep 02, 2026, 08:23 PM UTC
M
Johnson & Johnson shares jump after UBS raises target to $320
Johnson & Johnson surged roughly 1.2% to $274.395 as UBS raised its price target from $280 to $320, with Barron's reporting the stock became a top Dow point contributor in early trading.
EQUITY | Sep 02, 2026, 04:46 PM UTC
M
UBS raises Johnson & Johnson price target to $320 from $280
UBS maintained Johnson & Johnson at Buy and raised its price target to $320.00 per share from $280.00, according to TradingView News via Benzinga ratings actions.
EQUITY | Sep 02, 2026, 01:51 PM UTC
L
JNJ to host investor conference call on third-quarter results
Johnson & Johnson will host an investor conference call focused on third-quarter results.
EQUITY | Aug 31, 2026, 09:12 PM UTC
L
Johnson & Johnson to host investor call on third-quarter results
Johnson & Johnson plans an investor conference call covering its third-quarter results.
EQUITY | Aug 31, 2026, 09:08 PM UTC
L
J&J's China Pill Win Challenges Its Own Injection Franchise
J&J's China Pill Win Challenges Its Own Injection Franchise
GEOPOLITICS | Aug 28, 2026, 05:26 PM UTC
M
GILD, ROIV win FDA nod in weekly biotech buzz
Weekly Buzz highlights FDA nods for GILD and ROIV; also cites a BHVN/LLY deal and SYRE missing a monotherapy goal.
REGULATION | Aug 28, 2026, 02:57 PM UTC
M
China approves J&J oral psoriasis pill, drugmaker says
China approved J&J’s oral psoriasis pill, the drugmaker said.
GEOPOLITICS | Aug 27, 2026, 08:54 AM UTC
L
J&J's First Anemia Approval Meets a $652 Billion Reality
J&J's First Anemia Approval Meets a $652 Billion Reality
EQUITY | Aug 26, 2026, 06:56 PM UTC
L
FDA early alert cites Abiomed heart pump controller purge cassette issue
TradingView News reports the FDA issued an early alert regarding a purge cassette issue for an Abiomed heart pump controller.
REGULATION | Aug 26, 2026, 06:01 PM UTC
H
FDA approves J&J IMAAVY (nipocalimab-aahu) for wAIHA
Johnson & Johnson says the FDA approves IMAAVY (nipocalimab-aahu) as a first-ever treatment for warm autoimmune hemolytic anemia (wAIHA).
REGULATION | Aug 24, 2026, 11:13 PM UTC
M
Dow Jones closes 0.22% lower as Caterpillar, Nvidia lead declines
The Dow Jones Index fell 116 points, or 0.22%, to close at 53,344 on Tuesday, with Caterpillar, Nvidia and Boeing leading the declines.
EQUITY | Aug 18, 2026, 08:35 PM UTC
M
Dow Jones opens 0.26% lower as Caterpillar, Nvidia fall
The Dow Jones Index is down 139 points at the open, with Caterpillar, Nvidia and Home Depot leading declines while J&J, IBM and Chevron gain.
EQUITY | Aug 18, 2026, 01:40 PM UTC
H
Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’
On CNBC’s “ Mad Money Lightning Round,” Jim Cramer said Lockheed Martin Corporation (NYSE: LMT ) is “sensational” and its CEO is “fantastic.” According to recent news, the company received a major U.S. government contrac
EARNINGS | Aug 07, 2026, 12:14 PM UTC
H
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
New York Governor Kathy Hochul (D) said President Donald Trump’ s decision to end a Medicare subsidy program will raise prescription drug costs for about 1.3 million New Yorkers, arguing seniors should not have to bear t
GEOPOLITICS | Aug 06, 2026, 07:41 AM UTC
M
Johnson & Johnson Executive Vice President Jennifer Taubert to Retire
Johnson & Johnson executive vice president retires
EQUITY | Aug 04, 2026, 12:52 PM UTC
H
Goldman Adds AMAT, MSFT to Conviction List
Goldman adds stocks to conviction list
EQUITY | Aug 03, 2026, 12:21 PM UTC
H
Goldman Adds AMAT, MSFT to US Conviction Buy List
Goldman updates US Conviction Buy list with new additions
EQUITY | Aug 03, 2026, 10:14 AM UTC
H
AAPL, JNJ, LLY, NFLX, PM, ABBV decline
Major stocks decline
EQUITY | Jul 30, 2026, 02:08 PM UTC
L
JNJ - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-cla
JNJ - Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck canc
REGULATION | Jul 30, 2026, 12:31 PM UTC
H
JNJ Acquires Firefly Bio
JNJ acquires Firefly Bio to advance oncology innovation
MNA | Jul 30, 2026, 01:10 AM UTC
H
JNJ - earlier PR: Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Car-T Programs and Transform Autoimmun
JNJ - earlier PR: Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Car-T Programs and Transform Autoimmune Disease Through Immune Reset -Johnson & Johnson Partners With Sail Biomedicine
EARNINGS | Jul 30, 2026, 01:09 AM UTC
H
JNJ Acquires Firefly Bio
JNJ buys Firefly Bio for oncology innovation
MNA | Jul 29, 2026, 09:51 PM UTC
H
JNJ Collaborates with Sail Biomedicines
JNJ partners with Sail Biomedicines
EQUITY | Jul 29, 2026, 09:31 PM UTC
L
JNJ Raise PT to $300 from $290 after talc settlement @ Argus
JNJ Raise PT to $300 from $290 after talc settlement @ Argus
EQUITY | Jul 29, 2026, 12:03 PM UTC
L
JNJ Shares of Johnson & Johnson are up more than 2% after the Healthcare giant agreed to pay $5.5B to settle thousands of lawsuits alleging
JNJ Shares of Johnson & Johnson are up more than 2% after the Healthcare giant agreed to pay $5.5B to settle thousands of lawsuits alleging some of its talc products caused ovarian cancer. Club holding J&j said the claim
EQUITY | Jul 28, 2026, 01:10 PM UTC
H
Morning Movers: Corning sinks and Boeing gains after quarterly results
Stock futures are mixed this morning as investors brace for a pivotal stretch of earnings and the start of the Federal Reserve's two-day policy meeting, with renewed concerns over artificial intelligence spending and ris
EARNINGS | Jul 28, 2026, 01:00 PM UTC
L
JNJ Johnson & Johnson introduces monarch™ platform to the middle East
JNJ Johnson & Johnson introduces monarch™ platform to the middle East
EQUITY | Jul 28, 2026, 12:52 PM UTC